Phase II Study of the PARP Inhibitor BMN 673 (Talazoparib Tosylate) in Advanced Cancer Patients With Somatic Alterations in BRCA1/2, Mutations/Deletions in PTEN or PTEN Loss, a Homologous Recombination Defect, Mutations/Deletions in Other BRCA Pathway Genes and Germline Mutation in BRCA1/2 (Not Breast or Ovarian Cancer)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 May 2017
At a glance
- Drugs Talazoparib (Primary)
- Indications Cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 05 Feb 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 24 Nov 2015 Planned number of patients changed from 180 to 270 as reported by ClinicalTrials.gov.